Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: mitochondrial disorders therapeutics - Mitopharm/Abliva

Next Previous
Search
Drug Profile

Research programme: mitochondrial disorders therapeutics - Mitopharm/Abliva

Alternative Names: Ciclosporin derivatives - Abliva; mPT inhibitors; NICAM; NVP 016; NVP 017

Latest Information Update: 05 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitopharm Limited; NeuroVive Pharmaceutical
  • Developer Abliva; Mitopharm Limited
  • Class Antineoplastics; Cardiovascular therapies; Ciclosporins; Obesity therapies
  • Mechanism of Action Cyclophilin D inhibitors; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute heart failure; Cancer; Obesity; Stroke

Most Recent Events

  • 28 May 2020 NeuroVive Pharmaceutical is now called Abliva
  • 21 Feb 2019 NeuroVive Pharmaceutical enters into an exclusive agreement with Oroboros Instruments to license and supply two of its first generation of succinate/malonate prodrugs originating from NVP 015 program
  • 04 Nov 2017 No recent reports of development identified for research development in Acute-heart-failure in Sweden (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top